🇺🇸 FDA
Patent

US 11492624

RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

granted A61KA61K9/0019

Quick answer

US patent 11492624 (RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1) held by Arrowhead Pharmaceuticals, Inc. expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K9/0019